Log In
Print
BCIQ
Print
Print this Print this
 

ondansetron (RHB-102)

  Manage Alerts
Collapse Summary General Information
Company RedHill Biopharma Ltd.
DescriptionOnce-daily controlled release tablet formulation of ondansetron, a serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEmesis
Indication DetailsPrevent nausea and vomiting in cancer patients; Treat chemotherapy- and radiotherapy-induced nausea and vomiting
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today